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Antiarrhythmic Action of Labetalol and Its Effect on Adenine
Metabolism in the Isolated Rat Heart
WILHELM F. LUBBE, MD, FRACP, FACC, TUAN NGUYEN, BS, MARGOT F. EDWARDS , MS
Auckland. New Zealand
Labetalol, a combined alpha- and beta-adrenergic an-
tagonist, was assessed for antiarrhythmic activity in the
isolated perfused rat heart. Inclusion of 5.0 and 7.5 ILmol!
liter labetalol in the perfusate reduced the fall in ven-
tr icular fibrillation threshold and eliminated ventricular
arrhythmias during the coronar y occlusion period of 15
minutes. In treated hearts, levels of high energy phos-
phates were significantly higher and lactate, adenosine
and hypoxanth ine levels were lower in ischemic myo-
cardium. Cyclic adenosine monophosphate levels were
reduced in uninvolved myocardium (0.31 ± 0.01 and
0.24 ± 0.02 versus 0.43 ± 0.02 nmol/g fresh weight)
and in the ischemic myocardium (0. 38 ± 0.02 and 0.34
Labetalol (5- I-hydroxy-methyl-3-phenylpropylaminoethyl-
salicylamide) competitively antagonizes both alpha- and beta-
adrenerg ic receptors (I) . Unlike the beta-adrenoceptor an-
tagonists, it decreases rather than increases the peripheral
vascular resistance as blood pressu re is lowered in the intact
dog (I) and human beings (2-4) . The decrease in arterial
resistance is also found in the coronary arter ies ; an increase
in coro nary flow rate occurs after labetalol administration
in dogs (5) and human beings with coronary arterial disease
(4). In rats subjected to coronary artery ligation, labetalol
reduces loss of creatine kinase from myocardium and re-
duces myocardia l necrosis (6). In two clinica l studies (7,8),
Iabetalol relieved chest pain in patients with coex istent ar-
terial hypertension and angina pec toris .
Several beta-adrenergic receptor blocking agents sup-
press arrhythmias during the ear ly phase of coronary oc-
clusion (9) . Some alpha-adrenergic receptor blocking agents
possess activity against reperfusion ventricular arrhythmias
(10) , a property not encountered among the beta-adrenergic
antago nists. Labetalol , with both alpha- and beta-adrenergic
antago nist actio ns may , therefore , possess unique propert ies
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± 0.04 versus 0.65 ± 0.05 nmol/g) in hearts treated
respectively with 5.0 and 7.5 ILmol/liter labetalol versus
control hearts. When untreated hearts were perfused
with 3.0 mmol/liter potassium in perfusate, all had ven-
tricular tachycardia or fibrillation during coronary lig-
ation and developed ventricular fibrillation after reper-
fusion. Labetalol, 5.0 ILmol/litcr , reduced ventricular
tachyarrhythmias during coronary occlusion and after
reperfusion, whereas labetalol, 7.5 ILmol/liter, elimi-
nated tachyarrhythmias durin g occlusion and reperfu-
sion. Labetalol had potent antiarrhythmic activity in the
hearts rendered uniformly prone to arrhythmias by per-
fusion with a low potassium solution.
as an antiarrhythmic agent. We used the isolated perfused
rat heart with measurement of the ventricular fibrillation
threshold and quantification of spontaneous arrhythmias during
coronary artery occlusion and afte r myocardial reperfusion
to assess whether labetalol has antiarrhythmic act ivity . The
influence of this agent on high energy phosphates, cyclic
adenosine monophosphate and adenine metabolites in the
first 15 minutes of ischemia was also investigated.
Methods
Experimental preparation. The procedures involved
in the perfusion and biochem ical preparation of these rat
hearts have been described in detail ( 11, 12). Male Wis tar
rats (200 to 300 g) were anesthetized with methoxyflurane
and given 200 IU heparin intravenously. The hearts were
rapidly excised, placed in ice-co ld perfusate and mounted
for perfusion by the Langendorff technique . The perfusate
was Krebs-Henseleit bicarbonate buffer. continuously gassed
with 95% oxygen and 5% carbo n dioxide and maintained
at 37°C. The substrate was d-g lucose , II rnmol/liter: the
perfusate potassium concentratio ns were 5 .9 mmollliter
(normal K +) and 3.0 mmol/l iter (low K +). The perfusion
column was 100 cm in height. A 4-0 silk suture was placed
deep to the left coronary artery for its ligation later in the
experi ment. A period of 30 minutes of perfusion was al-
lowed for stabilization before heart rate and coronary flow
rates were estimated.
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Estimation of ventricular fibrillation threshold. After
stabilization, the ventricular fibrillation threshold was ob-
tained by the single stimulus technique. Thin platinum wire
electrodes (36 standard wire gauge) were inserted subepi-
cardially at the apex and base of the left ventricle, remote
from the myocardium likely to be involved by ischemia
after coronary ligation. The electrocardiogram was obtained
by inserting thin copper wire electrodes into the right atrium
and ventricle . The heart was monitored continuously on a
Tektronix memory oscilloscope and a continuous electro-
cardiogram was recorded at 5.0 mm/s during the period of
coronary artery ligation and for 15 minutes after reperfusion
(Elema mingograph).
Stimuli were generated by a microprocessor-based stim-
ulus generator (Motorola 6800) programmed to deliver 2.0
ms square wave impulses at variable intervals after the onset
of the R wave which was used as a trigger. The ventricular
fibrillation threshold (minimal current required to precipitate
ventricular fibrillation lasting at least 6 cycles) was estimated
by scanning the region of the T wave with stimuli of initial
current strength of 3.0 rnA. Two stimuli were delivered at
2.5 ms intervals between 10 and 50 ms after the onset of
the R wave. The current strength was increased by 0.5 rnA
per series of stimuli across the T wave. When ventricular
fibrillation persisted, the heart was defibrillated with up to
two stimuli using the same current that precipitated the
arrhythmia; if this was unsuccessful, ice-cold Krebs-Hen-
seleit solution was applied to the heart until arrest occurred.
The heart invariably restarted in sinus rhythm . A recovery
period of 2 minutes was allowed before stimulation was
resumed.
Experimental procedure. Coronary artery occlusion was
obtained by abrupt tightening of the previously placed lig-
ature . Estimation of coronary flow rate, heart rate and ven-
tricular fibrillation threshold was performed at 15 minutes
after ligation. In the reperfused hearts, the ligature was
divided at this stage and the electrocardiogram recorded for
another IS minutes . In hearts destined for biochemical anal-
ysis, freeze clamping with liquid nitrogen cooled tongs by
the Wollenberger technique was performed 2 seconds after
injection of 0.2 ml disulfine blue (an intravascular dye)
immediately above the aortic perfusion cannula, as previ-
ously described (11,12).
In labetalol-treated hearts, perfusion was switched after
stabilization to Krebs-Henseleit solution containing 1.0,2.5 ,
5.0 or 7.5 J,Lmol/liter labetalol. The pure hydrochloride salt
was a fine white powder manufactured by Glaxo Group
Research Ltd. At these concentrations the powder dissolved
readily . In control experiments, the procedure was identical
except that the labetalol was omitted .
Scoring of spontaneous arrhythmias. The electrocar-
diograms recorded during the IS minute period of coronary
artery ligation and after reperfusion were analyzed for ven-
tricular arrhythmias, and the maximal score was allocated
to each heart as follows: I = bigeminal rhythm, couplets
or triplets of ventricular origin ; 2 = single episode of ven-
tricular tachycardia; 4 = multiple episodes of ventricular
tachycardia, but the heart was in sinus rhythm at 15 minutes;
6 = continuous ventricular tachycardia or single episode
of ventricular fibrillation; 8 = multiple .episodes of ven-
tricular fibrillation, but the heart was in sinus rhythm at IS
minutes and 10 = continuous ventricular fibrillation until
IS niinutes after ligation or reperfusion.
Biochemical estimations. After freeze clamping, the
ischemic and nonischemic myocardium were separated un-
der liquid nitrogen according to the distribution of the di-
sulfine blue (11,12). The frozen myocardium was powdered
in a liquid nitrogen-cooled percussion mortar. Aliquots of
tissue (50 to 100 mg) were extracted into 1 ml of ice-cold
6% weight/weight (w/w) perchloric acid using an Ultra-
Turrax blender (Jancke and Kunkel, Staufen). Extracts were
centrifuged for 15 minutes at 15,000 g and the supernatant
neutralized with a mixture of four parts 40% (w/w) potas-
sium hydroxide saturated with potassium carbonate and six
parts 0.2 M Tris-hydrochloride buffer, pH 7.5. The per-
chlorate precipitate was removed by centrifugation to yield
a clear supernatant and the metabolites nieasured in these
extracts. Adenosine triphosphate, creatine phosphate, aden-
osine, inosine, hypoxanthirie/xanthine and lactate were mea-
sured by standard enzymatic degradation techniques and
spectrophotometry (13). Tissue cyclic adenosine mono-
phosphate (cyclic AMP) was measured by the competitive
protein-binding assay of Tovey et al. (14). Each sample was
assayed on three occasions and values differing by less than
10% were used to calculate a mean value . Aliquots of pow"
dered heart tissue were used to determine the dry/wet weight
ratio, which was used to obtain the fresh weight (fresh
weight = dry weight x 5).
Substrates and enzymes were obtained as analytic grade
chemicals from Sigma Chemical Corporation. The cyclic
AMP assay kits were obtained from Amersham International
Ltd .
Statistical methods. The results obtained in each group
of hearts were expressed as the mean value ± the standard
error of the mean. Probability (p) values were obtained using
Student's t test (two-tailed test to compensate for unequal
variances) .
Results
Effects of coronary artery ligation in hearts perfused
with potassium, 5.9 mmol/liter. Coronary artery ligation
in 13 control hearts did not alter heart rate but did reduce
coronary flow rate from 9.6 ± 0.6 to 6.3 ± 0.5 mllmin
(p < 0.005). The ventricular fibrillation threshold was re-
duced from 8.0 ± 0.8 rnA before ligation to 3.0 ± 0.4
rnA at 15 minutes after ligation (p < 0.00 I). The arrhythmia
score during the occlusion period was 1.6 ± 0.5. Ventric-
ular fibrillation did not occur ; three hearts had multiple
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Discussion
Antiarrhythmic activity. In the isolated perfused rat
heart, inclusion of labetalol in the perfusate exerted a con-
centration-related protective effect against spontaneously
occurring ventricular arrhythmias during the period of coro-
Figure 1. Antiarrhythmic action of labetalol in hearts perfused
with low potassium (3.0 mmolliiter) in perfusate. During the oc-
clusion phase, arrhythmia scores (mean ± standard error of mean,
see text) were significantly reduced by labetalol, 2.5, 5.0 and 7,5
JLmollliter (p < 0.001 in each instance in comparison with the
score obtained in the control hearts), Similarly, after reperfusion,
the arrhythmia scores of IO and 9,8 (10 = maximal attainable)
in the control hearts and hearts treated with 1,0 JLmollliterlabetalol,
respectively, were significantlyreduced by 2,5, 5.0 and 7.5 JLmollliter
(p < 0,001 in comparison with control hearts), Because these
hearts were not freeze-clamped, the numbers in parentheses in-
dicate the number of hearts studied by reperfusion.
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myocardium, the level was reduced from 0.65 ± 0.05 nmol!
g fresh weight in the untreated hearts to 0.38 ± 0.02 nmol!
g in hearts treated with 5.0 JLmol!liter and to 0,34 ± 0.04
nmollg in hearts treated with 7.5 JLmol!liter (p < 0.001 in
both instances).
Antiarrhythmic effects of labetalol in hearts perfused
with low K "'. The antiarrhythmic effects of labetalol were
further investigated in hearts exposed to a reduced level of
K + (3.0 mmolliiter) in the perfusate. In 32 control hearts
perfused without labetalol, the arrhythmia score during the
period of coronary occlusion was 6.3 ± 0.5; 20 hearts
developed ventricular fibrillation, 15 of which had repeated
episodes or persistent ventricular fibrillation. After reper-
fusion, 28 of the 32 hearts had persistent ventricular fibril-
lation (arrhythmia score 9.8 ± 0,2). Ventricular fibrillation
threshold measurements were not performed in these ar-
rhythmia prone hearts, and because these hearts were sub-
jected to reperfusion, freeze clamping was not performed,
The antiarrhythmic effect of labetalol in concentrations
of J.0.2.5,5.0 and 7.5 umoliliter in the perfusate is shown
in Figure 1. A concentration-related reduction in arrhythmia
score was seen for arrhythmias occurring both during the
period of coronary occlusion and after reperfusion.
episodes of ventricular tachycardia, two had single episodes
of ventricular tachycardia and eight had no arrhythmias,
Severe reduction of the high energy phosphates. aden-
osine triphosphate and creatine phosphate was present in
the ischemic myocardium by 15 minutes after ligation (Table
I), The lactate content of ischemic myocardium was in-
creased 20-fold, The adenine metabolites, adenosine, ino-
sine and hypoxanthine/xanthine were also increased about
10-fold in the ischemic myocardium, Cyclic adenosine mon-
ophosphate in the uninvolved myocardium was 0.43 ± 0.02
nmollg; in the ischemic myocardium the level was 0.65 ±
0.05 nmollg fresh weight (p < 0.001), These values were
consistent with those found in similiar studies in another
laboratory (l2).
Effects of labetalol in hearts perfused with normal
K+. Inclusion of 5.0 and 7.5 JLmol/liter labetalol in the
perfusate did not alter the heart rate before or after ligation.
The coronary flow rate was increased in hearts treated with
labetalol, 5.0 JLmollliter, both before (12.9 ± 1.2 versus
9.6 ± 0.6 mllmin) and after ligation (9.0 ± 0.8 versus 6.3
± 0.5 mllmin) (p < 0.05 in both instances). With 7.5 JLmoll
liter labetalol, the coronary flow rate was not significantly
altered. The ventricular fibrillation threshold was not altered
by labetalol treatment before coronary ligation, but was
significantly increased after ligation with labetalol, 5.0 JLmoll
liter (5.2 ± 0.8 versus 3.0 ± 0.4 rnA, p < 0.05) and with
7.5 JLmollliter"(9.2 ± 1.8, P < 0,005). All arrhythmias
were eliminated during the 15 minute period of coronary
occlusion with 5.0 JLmol/liter; the arrhythmia score was 0.2
± 0.2 in the hearts perfused with 7.5 JLmollliter of labetalol.
One heart in the treated series had a single episode of ven-
tricular tachycardia.
The high energy phosphates in uninvolved myocardium
were unaltered by labetalol. In ischemic myocardium, the
adenosine triphosphate and creatine phosphate content was
increased in hearts treated with both 5.0 and 7.5 JLmol!liter
labetalol (Table 1). The lower rate of high energy phosphate
depletion was supported by the observation that the lactate
content of ischemic myocardium was significantly decreased
in hearts treated with 5.0 JLmol!liter (22.1 ± 1.6 JLmollg)
and with 7.5 JLmol!liter of labetalol (20.9 ± 1.9 JLmol!g)
in comparison with the value in the untreated hearts (26.4
± 1.1 JLmol/g fresh weight) (p < 0.05 in both instances).
The adenosine, inosine and hypoxanthine/xanthine content
of nonischemic myocardium was unaltered by labetalol
treatment; the adenine metabolites were significantly de-
creased in ischemic myocardium of hearts treated with both
5.0 and 7.5 JLmol!liter labetalol. .
Major effects of labetalol were seen in the cyclic AMP
content of the nonischemic as well as of the ischemic myo-
cardium. The nonischemic myocardial cyclic AMP was re-
duced to 0.31 ± 0.01 nmol/g fresh weight with 5.0 JLmol!
liter labetalol, and to 0.24 ± 0.02 nmollg with 7.5 JLmoll
liter (p < 0.001 in both instances), compared with the level
of 0.43 ± 0.02 nmol!g in the untreated hearts. In ischemic
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Heart rate
(beats/min)
B
A
Coro nary now rate
(ml/min)
B
A
Arrhythmia score
(max = 10)
VFT
(rnA)
B
A
ATP
(J-Lmol/g)
U
I
Creaunc phosphate
(umol/g)
U
I
Lactate
(u rnol/g)
U
I
Adenosine
(/-Lmol!g)
U
I
Inosine
(u mol/g)
U
I
Hypoxanthine /xanthine
(/-Lmol!g)
U
I
Cyclic AMP
(nmol/g)
U
I
Control
(\ 3 hearts)
23 1 ::':: 15
217 ::':: 17
9. 6 ::':: 0 .6
6 .3 ::':: 0 .5
1.6 ± 0.6
8 ± 0.8
3 ± 0.4
3.2 ::':: 0.2
0 .44 ::':: 0 .04
2.3 ± 0.2
0 .22 ± 0 .02
0.9 ± 0 10
26.4 ± 1.10
0 .04 ::':: 0 .0 1
0.69 ± 0.07
0 .07 ± 0.01
0.91 ± 0.03
0 .03 ± 0.01
0 .28 ± 0.02
0.4 3 ::':: 0 .02
0 .65 ::':: 0 .05
5.0 /-Lmol/lite r
(10 hearts)
248 ± 7
243 ± 12
12.9 ± 1.2*
9 ± 0 .8*
O:j:
6.0 ± 0.6
5.2 ± 0 .8*
3.0 ± 0. 1
0.74 ± 0 .08t
2.6 ± 0 . 1
0 .46 ± 0 .10*
1.6 ± 0. 3
22. I ± I 6*
0.0 5 ::':: 0 .0 1
0 .54 ± 0.05
0.06 ± 0.01
0.68 ± 0.04t
0.02 ± 0.01
0 .21 :!: 0.02t
0 .31 ::':: 00 1:j:
0 .38 ::':: 0 .02:j:
7.5 /-LmoVhter
(10 hearts)
234 ::':: 16
223 ::':: 15
8.7 ± 0 .8
5.3 ± 0 .6
0.2 ± 0 .2t
10.0 ± 1.3
9.2 ± 1.8t
3.4 ± 0.2
0 .70 ::':: 0.05:1:
2. 1 ± 0 .3
0.3 8 ± O.04t
1.80 ± 0.42
20.9 ± 1.9*
0 .05 :!: 0 .0 1
0.4 9 ± 0 .06*
0.07 ±0 01
0.69 ± 0.04t
002 ± 0 .01
0.21 :!: o.cir
0.24 ::':: 0 .02 :j:
0.34 ::':: 0 .04 :j:
All biochemical values are expressed per gram of tissue , fresh weight (mean :t standard error of the mean)
• probability (p) < 0 .05; t p < 0.0 1; :j: P < 0 .001 (difference from control hearts)
A = 15 minutes after coronary ligation, AMP = adenosine monophosphare, ATI' = adenosine triphosphate. B = before coronary ligation; 1 = rschermc myocardium;
U = uninvolved myocardium; VFT = ventncular fibrillauon threshold.
nary occlusion and also against arrhythmias after reperfusion
of ischemic myocardium. The decrease of the ventricular
fibrillation threshold after coronary artery ligation was sig-
nificantly less in hearts exposed to labetalol. Labetalol there-
fore had antiarrhythmic activity according to each of the
criteria tested. The antiarrhythmic activity of labetalol was
sufficiently powerful to be effectiv e against the spontaneous
arrhythmias in hearts perfused with reduced perfusate K + ;
in those hearts not treated with labetalol , ventricular tachy-
cardia or fibrillation was uniformly prevalent during the
period of coronary occlusion and invariably occurred after
reperfusion .
Effect on heart rate and coronary Row. Relatively
minor or no effects were seen on heart rate and coronary
flow rate in the concentrations studied. The intermediate
concentration of labetalol (5.0 J-tlnolliiter) increased the
coronary flow rate, whereas the highest concentration stud-
ied (7. 5 J-tmoi/liter) did not. The significance of this diver-
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gent concentration-related effect of labetalol on coronary
flow is unclear. A possible explanation may reside in dif-
ferential receptor antagonism at different concentrations.
The increase in heart rate and coronary flow rate with 5.0
JLmollliter suggests that with this concentration alpha-re-
ceptor antagonism may have been more prominent relative
to beta-antagonism, which became more evident with 7.5
JLmollliter causing a return of heart rate and coronary flow
toward levels encountered in untreated hearts.
Biochemical effects. Labetalol significantly altered the
biochemical status of the ischemic myocardium in the hearts
with coronary artery ligation. The depletion of the high
energy phosphates (adenosine triphosphate and creatine
phosphate) and accumulation of lactate in ischemic myo-
cardium were reduced by labetalol. The reduction of lactate
accumulation and the lower extent of high energy phosphate
depletion encountered in labetalol-treated hearts is consist-
ent with an improvement by labetalol of residual perfusion
in the ischemic myocardium. Labetalol effects were also
seen on adenosine, inosine and hypoxanthine/xanthine, the
content of which was reduced in ischemic myocardium.
Labetalol caused a highly significant reduction of the cyclic
adenosine monophosphate (cyclic AMP) content in both
nonischemic and ischemic myocardium. The levels of cyclic
AMP recorded in these labetalol treated hearts were similar
to those in hearts treated with amiodarone (II) and dl-
propranolol (12). The antiarrhythmic effect of labetalol in
the isolated rat heart was, therefore, like that of propranolol
and amiodarone in this model, accompanied by a reduction
in ischemic myocardial cyclic AMP levels.
Mechanisms of labetalol's effects. The possibility that
labetalol was antiarrhythmic by virtue of its membrane sta-
bilizing activity cannot be entirely excluded, but is unlikely.
Membrane stabilization with labetalol occurs with concen-
trations in perfusate of about 10 JLmollliter (I). It is con-
siderably less potent than propranolol in this action (I) yet
exerts significant antiarrhythmic activity, especially against
reperfusion arrhythmias, an effect that we were unable to
demonstrate with propranolol.
The powerful inhibitory effect oflabetalol on reperjusion
arrhythmias resembles that of amiodarone (11) and the al-
pha-adrenergic antagonists: phentolamine, prazosin (10) and
nifedipine (16). The alphalytic component of labetalol may
confer on it this valuable action which has not been dem-
onstrated among the beta-adrenergic antagonists (15). It is
of interest that antiarrhythmic action against reperfusion
ventricular fibrillation has also been recorded with other
agents that share vasodilator properties, that is, amiodarone
(11), verapamil (17) and nifedipine (15), even though their
mechanisms of action are likely to be different.
The effect of labetalol on cyclic AMP may be important
for its action on ouabain-toxic arrhythmias (1). Tanz et al.
(18) have recently demonstrated that the arrhythmias en-
countered in ouabain-toxic guinea pig hearts are associated
with increased myocardial levels of cyclic AMP. The an-
tiarrhythmic action of labetalol on coronary occlusion ar-
rhythmias (associated with markedly reduced levels of cyclic
AMP in ischemic myocardium) provides additional support
for the hypothesis linking the antiarrhythmic actions of such
agents as propranolol (10) and amiodarone (II) to their
actions of reducing cyclic AMP accumulation in ischemic
myocardium (19).
Clinical implications. These observations on labetalol
in the isolated rat heart may have important clinical impli-
cations. With its actions of increasing coronary perfusion
in dogs (5) and in patients with coronary artery disease (4),
its improvement of exercise tolerance in patients with isch-
emic heart disease after intravenous administration (2) and
reduction of angina pectoris in hypertensive patients (7,8)
labetalol may have an important therapeutic role in ischemic
heart disease. The antiarrhythmic effects and preservation
of ischemic myocardial high energy phosphate content seen
in the present study support the observations in which la-
betalol limited ischemic damage in rats with coronary li-
gation (6). The potent antiarrhythmic effect shown in the
hearts perfused with a reduced potassium concentration, and
therefore highly prone to ventricular fibrillation, may have
important implications for patients developing myocardial
ischemia in the presence of potassium depletion: for ex-
ample, after energetic diuretic therapy. Two uncontrolled
clinical studies (20,21) have suggested that labetalol may
have effective antiarrhythmic activity. Intravenous infusion
of labetalol restored sinus rhythm in 9 of 11 patients with
life-threatening arrhythmias and also caused a decrease in
blood pressure. This agent clearly deserves controlled clin-
ical investigation in patients with ischemic heart disease.
We thank Elizabeth West for technical assistance The labetalol powder
was kindly supphed by Glaxo-Allenbury (NZ) Pty. Ltd
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